Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: Contribution to severe gastrointestinal tract dysmotility

Annals of the Rheumatic Diseases

Volumn 68, Issue 5, 2009, Pages 710-714

  Kawaguchi, Y ^a   Nakamura, Y ^b   Matsumoto, I ^b   Nishimagi, E ^a   Satoh, T ^c   Kuwana, M ^c   Sumida, T ^b   Hara, M ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR AUTOANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; FISHER EXACT TEST; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; SYSTEMIC SCLEROSIS; AUTOIMMUNE DISEASE; BLOOD; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MIDDLE AGED; RECEPTOR, MUSCARINIC M3; SCLERODERMA, SYSTEMIC;

EID: 66149090427     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.096545     Document Type: Article

References (17)

1. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008;53:1163-1174
2. Nishimagi E, Tochimoto A, Kawaguchi Y, Satoh T, Kuwana M, Takagi K, et al. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 2007;34:2050-2055 (Pubitemid 47548209)
3. Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol 2008;42:5-12.
4. Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 2002;123:1144-1150
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590
6. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205 (Pubitemid 18073738)
7. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558 (Pubitemid 34539104)
8. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-1285
9. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-2167 (Pubitemid 29487010)
10. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-407
12. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83. (Pubitemid 24027696)
13. Naito Y, Matsumoto I, Wakamatsu E, Goto D, Sugiyama T, Matsumura R, et al. Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome. Ann Rheum Dis 2005;64:510-511 (Pubitemid 40283080)
14. Nakamura Y, Wakamatsu E, Matsumoto I, Tomiita M, Kohno Y, Mori M, et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjögren syndrome. Ann Rheum Dis 2008;67:136-137
15. Kovács L, Marczinovits I, György A, Tóth GK, Dorgai L, Pál J, et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3 in primary Sjogren's syndrome. Rheumatology 2005;44:1021-1025 (Pubitemid 41487176)
16. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2000;43:1647-1654 (Pubitemid 30452487)
17. Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A 2000;97:9579-9584 (Pubitemid 30650818)